Macromolecular Changes in Nilotinib Resistant K562 Cells; an in Vitro Study by Fourier Transform Infrared Spectroscopy

dc.contributor.author Ceylan, Çağatay
dc.contributor.author Camgöz, Aylin
dc.contributor.author Baran, Yusuf
dc.coverage.doi 10.7785/tcrt.2012.500281
dc.date.accessioned 2017-05-29T06:54:03Z
dc.date.available 2017-05-29T06:54:03Z
dc.date.issued 2012
dc.description.abstract Nilotinib is a second generation tyrosine kinase inhibitor which is used in both first and second line treatment of chronic myeloid leukemia (CML). In the present work, the effects of nilotinib resistance on K562 cells were investigated at the molecular level using Fourier transform infrared (FT-IR) spectroscopy. Human K562 CML cells were exposed to step-wise increasing concentrations of nilotinib, and sub-clones of K562 cells resistant to 50 nM nilotinib were generated and referred to as K562/NIL-50 cells. Antiproliferative effects of nilotinib were determined by XTT cell proliferation assay. Changes in macromolecules in parental and resistant cells were studied by FT-IR spectroscopy. Nilotinib resistance caused significant changes which indicated increases in the level of glycogen and membrane/lipid order. The amount of unsaturated lipids increased in the nilotinib resistant cells indicating lipid peroxidation. The total amount of lipids did not change significantly but the relative proportion of cholesterol and triglycerides altered considerably. Moreover, the transcriptional status decreased but metabolic turn-over increased as revealed by the FT-IR spectra. In addition, changes in the proteome and structural changes in both proteins and the nucleus were observed in the K562/NIL-50 cells. Protein secondary structural analyses revealed that alpha helix structure and random coil structure decreased, however, anti-parallel beta sheet structure, beta sheet structure and turns structure increased. These results indicate that the FT-IR technique provides a method for analyzing drug resistance related structural changes in leukemia and other cancer types. en_US
dc.description.sponsorship TUBITAK (107S317); Turkish Academy of Sciences en_US
dc.identifier.citation Ceylan, Ç, Camgöz, A. and Baran, Y. (2012). Macromolecular changes in nilotinib resistant k562 cells; An in vitro study by fourier transform infrared spectroscopy. Technology in Cancer Research and Treatment, 11(4), 333-344. doi:10.7785/tcrt.2012.500281 en_US
dc.identifier.doi 10.7785/tcrt.2012.500281 en_US
dc.identifier.doi 10.7785/tcrt.2012.500281
dc.identifier.issn 1533-0346
dc.identifier.issn 1533-0338
dc.identifier.scopus 2-s2.0-84863913864
dc.identifier.uri http://dx.doi.org/10.7785/tcrt.2012.500281
dc.identifier.uri https://hdl.handle.net/11147/5620
dc.language.iso en en_US
dc.publisher SAGE Publications Inc. en_US
dc.relation info:eu-repo/grantAgreement/TUBITAK/TBAG/SBAG/107S317 en_US
dc.relation.ispartof Technology in Cancer Research and Treatment en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Nilotinib en_US
dc.subject Tyrosine kinase inhibitor resistance en_US
dc.subject Chronic myeloid leukemia en_US
dc.subject Fourier transform infrared spectroscopy en_US
dc.subject Triacylglycerol en_US
dc.title Macromolecular Changes in Nilotinib Resistant K562 Cells; an in Vitro Study by Fourier Transform Infrared Spectroscopy en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.institutional Ceylan, Çağatay
gdc.author.institutional Camgöz, Aylin
gdc.author.institutional Baran, Yusuf
gdc.author.yokid 45775
gdc.author.yokid 119193
gdc.bip.impulseclass C4
gdc.bip.influenceclass C5
gdc.bip.popularityclass C5
gdc.coar.access open access
gdc.coar.type text::journal::journal article
gdc.collaboration.industrial false
gdc.description.department İzmir Institute of Technology. Food Engineering en_US
gdc.description.endpage 344 en_US
gdc.description.issue 4 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q3
gdc.description.startpage 333 en_US
gdc.description.volume 11 en_US
gdc.description.wosquality Q2
gdc.identifier.openalex W2160734366
gdc.identifier.pmid 22712605
gdc.identifier.wos WOS:000306499500004
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed
gdc.oaire.accesstype GOLD
gdc.oaire.diamondjournal false
gdc.oaire.impulse 5.0
gdc.oaire.influence 3.0845646E-9
gdc.oaire.isgreen true
gdc.oaire.keywords Tyrosine kinase inhibitor resistance
gdc.oaire.keywords Chronic myeloid leukemia
gdc.oaire.keywords Fusion Proteins, bcr-abl
gdc.oaire.keywords Fourier transform infrared spectroscopy
gdc.oaire.keywords Antineoplastic Agents
gdc.oaire.keywords Nilotinib
gdc.oaire.keywords Triacylglycerol
gdc.oaire.keywords Pyrimidines
gdc.oaire.keywords Drug Resistance, Neoplasm
gdc.oaire.keywords Leukemia, Myelogenous, Chronic, BCR-ABL Positive
gdc.oaire.keywords Spectroscopy, Fourier Transform Infrared
gdc.oaire.keywords Humans
gdc.oaire.keywords Drug Screening Assays, Antitumor
gdc.oaire.keywords K562 Cells
gdc.oaire.keywords Protein Kinase Inhibitors
gdc.oaire.keywords Cell Proliferation
gdc.oaire.popularity 2.806692E-9
gdc.oaire.publicfunded false
gdc.oaire.sciencefields 0301 basic medicine
gdc.oaire.sciencefields 03 medical and health sciences
gdc.oaire.sciencefields 0302 clinical medicine
gdc.openalex.collaboration National
gdc.openalex.fwci 1.36966193
gdc.openalex.normalizedpercentile 0.8
gdc.opencitations.count 11
gdc.plumx.crossrefcites 11
gdc.plumx.mendeley 23
gdc.plumx.pubmedcites 2
gdc.plumx.scopuscites 13
gdc.scopus.citedcount 13
gdc.wos.citedcount 13
relation.isAuthorOfPublication.latestForDiscovery 8d2af00e-811a-4351-a3f3-a7f0b1847021
relation.isOrgUnitOfPublication.latestForDiscovery 9af2b05f-28ac-4013-8abe-a4dfe192da5e

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Name:
5620.pdf
Size:
1.49 MB
Format:
Adobe Portable Document Format
Description:
Makale

License bundle

Now showing 1 - 1 of 1
Loading...
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: